 |
| |
| For Immediate Release |
| |
Prodesse,
Inc. and Invitrogen Collaborate on First Molecular Diagnostic
LUX™ Products
Waukesha, WI and Carlsbad, CA, July 21, 2006 – Prodesse, Inc., a
Wisconsin-based global leader in Multiplex PCR, and Invitrogen Corporation,
a provider of essential life science technologies for disease research
and drug discovery, today announced the signing of a license agreement
for the first diagnostic assays with Invitrogen’s LUX™ technology.
Utilizing Prodesse's global distribution capabilities the partnership positions
Invitrogen’s technologies in new market segments, serving a new customer
base.
LUX™ (Light Upon eXtension) reagents are an essential starting point
for a broad scope of drug discovery and molecular diagnostic applications
including gene expression studies, biomarker analysis and functional genomics
experiments. By providing improved sensitivity and specificity over traditional
methods of analysis and the ability to examine multiple targets in one
experiment, LUX™ was developed to meet the demanding needs of these
varied applications
" As we continue to rapidly increase our real-time products menu, access
to Invitrogen's LUX™ platform is an important milestone,” said Tom
Shannon, President & CEO of Prodesse. “Now we can provide our customers
with a technology that has significant design flexibility as well the tremendous
advantage of conveying service rights that do not carry royalty burdens to end
users.”
“ Invitrogen’s partnership with Prodesse is a natural evolution of
our proven technology platforms and allows us to better serve our customers through
collaborations with innovative diagnostic providers,” said Gregory T. Lucier,
Chairman and CEO of Invitrogen Corporation. “Scientists in basic research
and drug discovery and development have already found our LUX technology to produce
more reliable data than many of the other quantitative PCR chemistries available.
Our partnership will broaden the reach of this technology into clinical laboratories
around the world.
Licensing and cost constraints have limited many companies in the molecular
diagnostics market. Invitrogen’s unique technologies enable companies
like Prodesse to provide their customers with state-of-the-art molecular
diagnostic products. Invitrogen’s LUX™ technology, combined
with SuperScript® III Reverse Transcriptase and the new Platinum® Tfi
DNA Polymerase, provides a powerful and complete solution for assay development.
For additional information, please visit Prodesse at booth # 106 and Invitrogen
at booth # 2071 and 2072 at the American Association of Clinical Chemistry
(AACC) Annual Lab Expo July 23-26, 2006 in Chicago, IL. AACC is an international
scientific/medical society of clinical laboratory professionals, physicians,
research scientists and other individuals involved with clinical chemistry
and related disciplines. Founded in 1948, the society has 10,000 members
and is headquartered in Washington, DC. |
|
About Prodesse
Prodesse is a biotechnology company focused on developing analyte specific
reagents that can be used by CLIA certified laboratories to develop
assays for detecting infectious disease pathogens. The Company's
reagents incorporate proprietary technology that allows for the detection
of multiple pathogens. Prodesse currently offers nine different multiplex
products covering 33 different organisms. The company’s products
can be used on a variety of detection platforms. The Company sells
its reagents to laboratories throughout the US and the world, and
also operates a CLIA certified laboratory for testing services in
the Midwest area. For more information about Prodesse and its products,
call 888-589-6974 or go to www.prodesse.com.
About Invitrogen Corporation
Invitrogen Corporation (NASDAQ:IVGN) provides products and services that
support academic and government research institutions and pharmaceutical
and biotech companies worldwide in their efforts to improve the human
condition. The company provides essential life science technologies for
disease research, drug discovery, and commercial bioproduction. Invitrogen's
own research and development efforts are focused on breakthrough innovation
in all major areas of biological discovery including functional genomics,
proteomics, bioinformatics and cell biology -- placing Invitrogen's products
in nearly every major laboratory in the world. Founded in 1987, Invitrogen
is headquartered in Carlsbad, California, and conducts business in more
than 70 countries around the world. The company globally employs approximately
4,800 scientists and other professionals and had revenues of approximately
$1.2 billion in 2005. For more information, visit www.invitrogen.com.
Safe Harbor Statement
Certain statements contained in this press release are considered "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, and it is Invitrogen's intent that such statements
be protected by the safe harbor created thereby. Forward-looking statements
include, but are not limited to, the statement that this partnership
will broaden the reach of this technology into clinical laboratories
around the world. Potential risks and uncertainties include, but are
not limited to, the risk that the collaboration will not successfully
extend the reach of Invitrogen's technologies, as well as other risks
and uncertainties detailed from time to time in Invitrogen's Securities
and Exchange Commission filings.
For additional information regarding this announcement, please contact:
|
| |
| |
Press Contact:
Andy Shrago, Chief Marketing Officer
Prodesse, Inc.
Phone: (262) 446-0700
Email: ashrago@prodesse.com
Eric Endicott
Public Relations Manager
Invitrogen Corporation
Phone: 760-268-7438
Email: eric.endicott@invitrogen.com
Carolyn Hawley
Porter Novelli Life Sciences
Phone: 858-527-3484
Email: chawley@pnlifesciences.com |
| |
|
| |
|
